---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-25-000120"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:39:28.824650+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mineralys prices upsized $250M public offering at $25.50/share

## Summary
- 9,803,921 shares at $25.50/share; total gross proceeds ~$250M.
- Net proceeds ~$234.7M (~$269.9M if underwriters' option exercised).
- Proceeds to fund lorundrostat clinical development, R&D, manufacturing, and pre-commercialization.
- Underwriters: BofA, Evercore, Goldman, Stifel, Wells Fargo; closing expected Sept 4, 2025.
- Upsized offering reflects strong demand; underwriters have 30-day option for 1.47M additional shares.

## SEC filing metadata
- accession: 0001933414-25-000120
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000120/0001933414-25-000120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000120/mlys-20250902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-25-000120
- JSON: https://secwatch.observer/filing/0001933414-25-000120.json
- Plain text: https://secwatch.observer/filing/0001933414-25-000120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.